For trans people who have been on testosterone for more than 10 years (when added up, not everyone has consistent access to care)
Rules:
AbstractContext. The effects of androgen therapy on arterial function in transgender men (TM) are not fully understood, particularly concerning long-term a
Conclusion
The TM group on long-term treatment with testosterone had higher aging-related aortic stiffening than the control groups. These findings indicate that aortic stiffness might be accelerated in the TM group receiving gender-affirming hormone treatment, and suggest a potential deleterious effect of testosterone on arterial function. Preventive measures in TM individuals receiving testosterone treatment, who are at higher risk for cardiovascular events, are highly recommended.
Why Pelvic Health Matters—and What Trans People Need to Know About It
This is an interview with a physical therapist who helps people with pelvic floor dysfunction and has worked with trans clients. The interview discusses the 5 S’s used to remember the functions of the pelvic floor, the potential effects hormones might have on those muscles over time, and how to best mitigate risks — aside from kegels. It’s really hard to find articles on this that aren’t by TERFs, and I appreciated the frank but respectful tone.
trying to find more info on safe storage of t in case of emergency
Testosterone Cypionate can be highly effective for treating low-t levels, but proper storage is crucial for its effectiveness. Follow our storage warnings.
this was one of the few links i could find that referenced the shelf life without just saying to look at the expiration date. everyone should have an extra portion of their meds for emergency rotated in their supply in my opinion. my doctor agrees but i want to do it safely and wisely.
any links or suggestions welcome
Transgender men on hormone therapy have a high incidence of PFD (94.1%) and experience a greater occurrence of urinary symptoms (86.7%).
Summary
An analysis of 68 transgender people taking testosterone found a high prevalence of pelvic floor dysfunction (PFD), with 94.1% of participants reporting symptoms. The most common issues were urinary symptoms, affecting a significant portion of the study group. This highlights the need for further research and awareness of PFD among transgender men undergoing hormone therapy. The document does not specify how long the participants were on hormones.
